Micromolecular methods for diagnosis and therapeutic strategy: a case study
Open Access
- 27 April 2018
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (32), 22862-22869
- https://doi.org/10.18632/oncotarget.25161
Abstract
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Morad Elbouchtaoui1, 2, Iulia Tengher3, Catherine Miquel1, 2, Charlotte Brugière1, Amélie Benbara4, Laurent Zelek5, 7, Marianne Ziol 3, 5, 6, Fatiha Bouhidel1, 2, Anne Janin1, 2, Guilhem Bousquet1, 5, 7, * and Christophe Leboeuf1, * 1Université Paris Diderot, Inserm, UMR_S1165, Paris, France 2Pathology Department, Hôpital St Louis, APHP, Paris, France 3Pathology Department, Hôpital Jean Verdier, APHP, Bondy, France 4Obstetrics and Gynecology Department, Hôpital Jean Verdier, APHP, Bondy, France 5Université Paris 13, Villetaneuse, France 6Inserm UMR_S1162, Paris, France 7Oncology Department, Hôpital Avicenne, APHP, Bobigny, France *Co-senior authors Correspondence to: Guilhem Bousquet, email: guilhem.bousquet@aphp.fr Christophe Leboeuf, email: christophe.leboeuf@univ-paris-diderot.fr Keywords: HER2 overexpressing breast cancer; micromethods; cancer therapy; laser-microdissection; trastuzumab-based treatment Received: July 03, 2017 Accepted: April 03, 2018 Published: April 27, 2018 ABSTRACT An intraductal carcinoma, 55 mm across, was diagnosed on a total mastectomy in a 45-year-old woman. The 2 micro-invasive areas found were too small for reliable immunostainings for estrogen, progesterone, and HER2 receptors. In the sentinel lymph-node, a subcapsular tumor embole of about 50 cancer cells was identified on the extemporaneous cryo-cut section, but not on further sections after paraffin-embedding of the sample. Considering this tumor metastatic potential, we decided to assess HER2 status on the metastatic embole using pathological and molecular micro-methods. We laser-microdissected the tumor cells, extracted their DNA, and performed droplet-digital-PCR (ddPCR) for HER2 gene copy number variation. The HER2/RNaseP allele ratio was 5.2 in the laser-microdissected tumor cells, similar to the 5.3 ratio in the HER2-overexpressing breast cancer cell line BT-474. We thus optimized the adjuvant treatment of our patient and she received a trastuzumab-based adjuvant chemotherapy.Keywords
This publication has 13 references indexed in Scilit:
- De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017Annals of Oncology, 2017
- Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional studyBreast Cancer Research and Treatment, 2017
- Human epidermal growth factor receptor 2 amplification detection by droplet digital polymerase chain reaction in formalin-fixed paraffin-embedded breast and gastric cancer samplesJournal of Cancer Research and Therapeutics, 2017
- Use of droplet digital PCR for quantitative and automatic analysis of the HER2 status in breast cancer patientsBreast Cancer Research and Treatment, 2016
- Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samplesExperimental and Molecular Pathology, 2016
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast CancerThe New England Journal of Medicine, 2015
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2013
- SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 casesBMC Cancer, 2013
- Droplet Digital PCR Measurement of HER2 Copy Number Alteration in Formalin-Fixed Paraffin-Embedded Breast Carcinoma TissueClinical Chemistry, 2013
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerThe New England Journal of Medicine, 2005